Par Drugs and Chemicals Limited

NSEI:PAR Stock Report

Market Cap: ₹2.5b

Par Drugs and Chemicals Management

Management criteria checks 3/4

Par Drugs and Chemicals' CEO is Jignesh Savani, appointed in Nov 2018, has a tenure of 6.08 years. total yearly compensation is ₹5.19M, comprised of 99.3% salary and 0.7% bonuses, including company stock and options. directly owns 42.36% of the company’s shares, worth ₹1.07B. The average tenure of the management team and the board of directors is 6.1 years and 6.4 years respectively.

Key information

Jignesh Savani

Chief executive officer

₹5.2m

Total compensation

CEO salary percentage99.3%
CEO tenure6.1yrs
CEO ownership42.4%
Management average tenure6.1yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

Earnings Working Against Par Drugs and Chemicals Limited's (NSE:PAR) Share Price Following 26% Dive

Dec 20
Earnings Working Against Par Drugs and Chemicals Limited's (NSE:PAR) Share Price Following 26% Dive

There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Oct 29
There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16
Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Apr 05
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Nov 03
Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

May 19
If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Mar 17
Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Oct 22
Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Aug 11
Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Jul 14
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Mar 31
Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Mar 05
Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Feb 06
Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Jan 10
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Dec 13
How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

CEO Compensation Analysis

How has Jignesh Savani's remuneration changed compared to Par Drugs and Chemicals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹183m

Jun 30 2024n/an/a

₹146m

Mar 31 2024₹5m₹5m

₹145m

Dec 31 2023n/an/a

₹142m

Sep 30 2023n/an/a

₹127m

Jun 30 2023n/an/a

₹115m

Mar 31 2023₹5mn/a

₹113m

Dec 31 2022n/an/a

₹103m

Sep 30 2022n/an/a

₹106m

Jun 30 2022n/an/a

₹91m

Mar 31 2022₹5m₹5m

₹92m

Dec 31 2021n/an/a

₹112m

Sep 30 2021n/an/a

₹112m

Jun 30 2021n/an/a

₹115m

Mar 31 2021₹4m₹4m

₹116m

Dec 31 2020n/an/a

₹88m

Sep 30 2020n/an/a

₹83m

Jun 30 2020n/an/a

₹65m

Mar 31 2020₹4mn/a

₹48m

Compensation vs Market: Jignesh's total compensation ($USD60.81K) is above average for companies of similar size in the Indian market ($USD42.16K).

Compensation vs Earnings: Jignesh's compensation has been consistent with company performance over the past year.

CEO

Jignesh Savani (47 yo)

6.1yrs

Tenure

₹5,185,000

Compensation

Mr. Jignesh Vallabhbhai Savani is Promoter of at Par Drugs and Chemicals Limited and has been its Chief Executive Officer since November 26, 2018 and serves as its Executive Director since February 26, 199...

Leadership Team

NamePositionTenureCompensationOwnership
Falgun Savani
Chairman of the Board & MD25.8yrs₹5.21m21.5%
₹ 543.5m
Jignesh Savani
CEO & Executive Director6.1yrs₹5.19m42.36%
₹ 1.1b
Chintan Chauhan
Chief Financial Officer6.1yrs₹589.00kno data
Sanket Trivedi
Company Secretary & Compliance Officer6.3yrs₹663.00kno data
Ghanshayambhai Savani
Whole Time Director6.1yrs₹5.18m6.52%
₹ 164.8m

6.1yrs

Average Tenure

47yo

Average Age

Experienced Management: PAR's management team is seasoned and experienced (6.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Falgun Savani
Chairman of the Board & MD25.8yrs₹5.21m21.5%
₹ 543.5m
Jignesh Savani
CEO & Executive Director25.8yrs₹5.19m42.36%
₹ 1.1b
Ghanshayambhai Savani
Whole Time Director12.7yrs₹5.18m6.52%
₹ 164.8m
Pravin Bhayani
Lead Independent Director5.9yrs₹1.29mno data
Kajal Vaghani
Independent Director5.9yrs₹40.00kno data
Krishna Shah
Independent Director5.9yrs₹90.00kno data
Nayna Savani
Non Executive Director6.8yrs₹50.00k3.08%
₹ 77.8m
Bintal Bhaveshkumar Shah
Independent Director4.3yrs₹25.00kno data

6.4yrs

Average Tenure

47.5yo

Average Age

Experienced Board: PAR's board of directors are considered experienced (6.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 11:45
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Par Drugs and Chemicals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution